| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
|
Blood
|
2009
|
23.52
|
|
2
|
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
|
J Clin Oncol
|
2003
|
17.67
|
|
3
|
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
|
Blood
|
2009
|
15.95
|
|
4
|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
|
Blood
|
2002
|
12.46
|
|
5
|
Cytogenetics in acute leukemia.
|
Blood Rev
|
2004
|
9.99
|
|
6
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
Blood
|
2009
|
5.87
|
|
7
|
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
|
Blood
|
2007
|
5.63
|
|
8
|
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2010
|
5.62
|
|
9
|
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
|
Blood
|
2006
|
5.40
|
|
10
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
11
|
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
|
Blood
|
2008
|
5.23
|
|
12
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
N Engl J Med
|
2008
|
4.91
|
|
13
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
14
|
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
4.34
|
|
15
|
Acquired copy number alterations in adult acute myeloid leukemia genomes.
|
Proc Natl Acad Sci U S A
|
2009
|
4.17
|
|
16
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2008
|
4.09
|
|
17
|
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
|
Blood
|
2008
|
3.89
|
|
18
|
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
|
Proc Natl Acad Sci U S A
|
2010
|
3.86
|
|
19
|
MicroRNA fingerprints during human megakaryocytopoiesis.
|
Proc Natl Acad Sci U S A
|
2006
|
3.80
|
|
20
|
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
|
Blood
|
2007
|
3.73
|
|
21
|
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
|
Cancer Cell
|
2005
|
3.44
|
|
22
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
Blood
|
2007
|
3.41
|
|
23
|
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2007
|
3.04
|
|
24
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
Blood
|
2008
|
3.03
|
|
25
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2011
|
3.01
|
|
26
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
J Clin Oncol
|
2008
|
2.98
|
|
27
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
J Clin Invest
|
2007
|
2.91
|
|
28
|
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2006
|
2.87
|
|
29
|
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
|
J Clin Oncol
|
2013
|
2.86
|
|
30
|
Acute Myeloid Leukemia.
|
N Engl J Med
|
2015
|
2.85
|
|
31
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2009
|
2.78
|
|
32
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
Blood
|
2008
|
2.63
|
|
33
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
Blood
|
2011
|
2.50
|
|
34
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
J Clin Oncol
|
2004
|
2.49
|
|
35
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
Blood
|
2008
|
2.46
|
|
36
|
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2005
|
2.41
|
|
37
|
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
|
Cancer Cell
|
2010
|
2.37
|
|
38
|
The prognostic and functional role of microRNAs in acute myeloid leukemia.
|
Blood
|
2010
|
2.33
|
|
39
|
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
Blood
|
2006
|
2.29
|
|
40
|
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
|
Nat Med
|
2006
|
2.23
|
|
41
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
Blood
|
2003
|
2.23
|
|
42
|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2005
|
2.16
|
|
43
|
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.
|
Blood
|
2003
|
2.13
|
|
44
|
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
|
Blood
|
2002
|
2.11
|
|
45
|
Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
|
Br J Haematol
|
2007
|
2.08
|
|
46
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
2.03
|
|
47
|
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
1.98
|
|
48
|
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
|
Blood
|
2012
|
1.97
|
|
49
|
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
|
Blood
|
2002
|
1.95
|
|
50
|
BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
|
J Clin Oncol
|
2006
|
1.87
|
|
51
|
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
|
J Natl Compr Canc Netw
|
2011
|
1.85
|
|
52
|
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
|
Blood
|
2007
|
1.83
|
|
53
|
Benchmarks in clinical productivity: a national comprehensive cancer network survey.
|
J Oncol Pract
|
2007
|
1.79
|
|
54
|
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
|
J Clin Oncol
|
2012
|
1.79
|
|
55
|
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.
|
Lancet
|
2004
|
1.79
|
|
56
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
Blood
|
2012
|
1.77
|
|
57
|
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.
|
Proc Natl Acad Sci U S A
|
2004
|
1.75
|
|
58
|
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
|
Blood
|
2006
|
1.74
|
|
59
|
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
|
Blood
|
2005
|
1.73
|
|
60
|
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.
|
Proc Natl Acad Sci U S A
|
2003
|
1.69
|
|
61
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
Blood
|
2007
|
1.64
|
|
62
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
J Clin Oncol
|
2009
|
1.63
|
|
63
|
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
Blood
|
2012
|
1.61
|
|
64
|
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
|
Blood
|
2012
|
1.59
|
|
65
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2010
|
1.59
|
|
66
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2008
|
1.57
|
|
67
|
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
|
Int J Oncol
|
2008
|
1.57
|
|
68
|
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.
|
J Clin Oncol
|
2006
|
1.57
|
|
69
|
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
|
Cancer
|
2004
|
1.54
|
|
70
|
Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.
|
J Clin Oncol
|
2003
|
1.54
|
|
71
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
Leuk Lymphoma
|
2014
|
1.53
|
|
72
|
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
|
Blood
|
2012
|
1.51
|
|
73
|
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.
|
Cancer Res
|
2008
|
1.49
|
|
74
|
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.49
|
|
75
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
Cancer
|
2013
|
1.48
|
|
76
|
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
|
Haematologica
|
2009
|
1.48
|
|
77
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
J Clin Oncol
|
2008
|
1.45
|
|
78
|
Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia.
|
Hematology Am Soc Hematol Educ Program
|
2006
|
1.42
|
|
79
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Blood
|
2010
|
1.41
|
|
80
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
Leuk Lymphoma
|
2008
|
1.39
|
|
81
|
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
|
Haematologica
|
2013
|
1.36
|
|
82
|
Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
|
Curr Opin Hematol
|
2005
|
1.36
|
|
83
|
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
|
J Clin Oncol
|
2013
|
1.34
|
|
84
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
85
|
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.
|
J Clin Oncol
|
2007
|
1.32
|
|
86
|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
|
J Clin Oncol
|
2004
|
1.32
|
|
87
|
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
|
Blood
|
2012
|
1.31
|
|
88
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.30
|
|
89
|
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
|
Clin Cancer Res
|
2013
|
1.30
|
|
90
|
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
|
Biol Blood Marrow Transplant
|
2011
|
1.29
|
|
91
|
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.
|
Blood
|
2002
|
1.29
|
|
92
|
Family history of cancer and incidence of acute leukemia in adults.
|
Am J Epidemiol
|
2002
|
1.26
|
|
93
|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
|
J Clin Oncol
|
2012
|
1.23
|
|
94
|
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
|
Blood
|
2004
|
1.20
|
|
95
|
Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q.
|
Genes Chromosomes Cancer
|
2002
|
1.20
|
|
96
|
Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
|
J Natl Cancer Inst Monogr
|
2008
|
1.19
|
|
97
|
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
|
J Clin Oncol
|
2004
|
1.19
|
|
98
|
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
|
Cancer
|
2004
|
1.18
|
|
99
|
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
|
J Clin Oncol
|
2013
|
1.15
|
|
100
|
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
|
Blood
|
2004
|
1.14
|
|
101
|
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
|
Curr Opin Oncol
|
2008
|
1.14
|
|
102
|
BAALC, a novel marker of human hematopoietic progenitor cells.
|
Exp Hematol
|
2003
|
1.13
|
|
103
|
Molecular signatures in acute myeloid leukemia.
|
Curr Opin Hematol
|
2009
|
1.13
|
|
104
|
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
|
Blood
|
2008
|
1.12
|
|
105
|
Myelodysplastic syndromes: clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2013
|
1.12
|
|
106
|
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
|
Blood
|
2011
|
1.12
|
|
107
|
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
|
J Clin Oncol
|
2004
|
1.11
|
|
108
|
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
|
Br J Haematol
|
2004
|
1.10
|
|
109
|
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
|
Blood
|
2007
|
1.10
|
|
110
|
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.
|
Blood
|
2012
|
1.07
|
|
111
|
Tobacco use among the Amish in Holmes County, Ohio.
|
J Rural Health
|
2008
|
1.06
|
|
112
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
Cancer
|
2012
|
1.06
|
|
113
|
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
|
Blood
|
2002
|
1.05
|
|
114
|
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
|
Blood
|
2012
|
1.04
|
|
115
|
Myelodysplastic syndromes clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
1.02
|
|
116
|
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
|
Cancer
|
2003
|
1.02
|
|
117
|
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
|
Curr Opin Hematol
|
2007
|
1.01
|
|
118
|
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
|
Clin Cancer Res
|
2002
|
1.00
|
|
119
|
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
|
Blood
|
2010
|
1.00
|
|
120
|
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
|
Blood
|
2013
|
0.99
|
|
121
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Cancer Chemother Pharmacol
|
2008
|
0.98
|
|
122
|
Low cancer incidence rates in Ohio Amish.
|
Cancer Causes Control
|
2009
|
0.97
|
|
123
|
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
|
Blood
|
2010
|
0.96
|
|
124
|
MicroRNA expression in acute myeloid leukemia.
|
Curr Hematol Malig Rep
|
2009
|
0.95
|
|
125
|
Cancer screening practices among Amish and non-Amish adults living in Ohio Appalachia.
|
J Rural Health
|
2010
|
0.94
|
|
126
|
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
Int J Oncol
|
2002
|
0.93
|
|
127
|
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
|
Int J Oncol
|
2006
|
0.93
|
|
128
|
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.
|
Cancer
|
2013
|
0.92
|
|
129
|
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2012
|
0.91
|
|
130
|
MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.
|
Best Pract Res Clin Haematol
|
2009
|
0.91
|
|
131
|
Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization.
|
Genes Chromosomes Cancer
|
2003
|
0.91
|
|
132
|
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.
|
Haematologica
|
2013
|
0.91
|
|
133
|
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
134
|
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Haematologica
|
2011
|
0.90
|
|
135
|
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
|
Blood
|
2011
|
0.89
|
|
136
|
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
|
Oncologist
|
2002
|
0.89
|
|
137
|
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
|
Invest New Drugs
|
2013
|
0.88
|
|
138
|
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
|
Blood
|
2014
|
0.87
|
|
139
|
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.
|
Leuk Res
|
2011
|
0.87
|
|
140
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
J Clin Invest
|
2014
|
0.86
|
|
141
|
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
|
Genes Chromosomes Cancer
|
2012
|
0.86
|
|
142
|
Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.85
|
|
143
|
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.
|
Leuk Res
|
2013
|
0.85
|
|
144
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
Blood
|
2012
|
0.84
|
|
145
|
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
|
Genes Chromosomes Cancer
|
2005
|
0.84
|
|
146
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
Haematologica
|
2013
|
0.83
|
|
147
|
Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line.
|
Blood
|
2002
|
0.83
|
|
148
|
Myelodysplastic syndromes.
|
J Natl Compr Canc Netw
|
2008
|
0.83
|
|
149
|
Dietary intake, food processing, and cooking methods among Amish and non-Amish adults living in Ohio Appalachia: relevance to nutritional risk factors for cancer.
|
Nutr Cancer
|
2011
|
0.82
|
|
150
|
Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
|
Eur J Haematol
|
2003
|
0.80
|
|
151
|
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.78
|
|
152
|
Acute myeloid leukaemia in 2012: En route to improved treatment options.
|
Nat Rev Clin Oncol
|
2013
|
0.78
|
|
153
|
The use of daily aspirin, nutritional supplements and alternative medications among Amish and non-Amish living in Ohio Appalachia.
|
Nutr Cancer
|
2012
|
0.77
|
|
154
|
Physical activity among Amish and non-Amish adults living in Ohio Appalachia.
|
J Community Health
|
2012
|
0.76
|
|
155
|
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
|
Cancer
|
2009
|
0.76
|
|
156
|
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
|
Int J Oncol
|
2004
|
0.75
|
|
157
|
Health literacy among the Amish: measuring a complex concept among a unique population.
|
J Community Health
|
2013
|
0.75
|
|
158
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
159
|
Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.
|
Haematologica
|
2014
|
0.75
|
|
160
|
Acute myeloid leukemia with adverse cytogenetic risk.
|
Oncology (Williston Park)
|
2012
|
0.75
|
|
161
|
Reply to K. Orendi et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
162
|
Hodgkin disease/lymphoma.
|
J Natl Compr Canc Netw
|
2008
|
0.75
|